A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

Turpie, Alexander G. G.; As, Gallus; Hoek, J A

doi:10.1016/s1062-1458(01)00291-4

Cited by 51 publications

(73 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Fondaparinux is the first selective factor Xa inhibitor approved for use in thromboprophylaxis after orthopedic surgery [15][16][17], and studies comparing fondaparinux to LMWH showed very useful thromboprophylaxis in patients after orthopedic surgery [16,17]. There are a few cases with massive bleeding in patients administered fondaparinux.…”

Section: Introductionmentioning

confidence: 99%

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

et al. 2012

View full text Add to dashboard Cite

We evaluated hemostatic markers in patients who underwent major orthopedic surgery, including total hip and total knee arthroplasty, and were treated for the prophylaxis of deep vein thrombosis (DVT) with or without fondaparinux (anti-Xa group, n = 98 and without anti-Xa group, n = 20). The frequency of DVT was significantly higher in the without anti-Xa group than in the anti-Xa group, but the reduction of hemoglobin and fibrinolytic marker levels was significantly lower in the without anti-Xa group than in the anti-Xa group. Eighteen patients in the anti-Xa group showed a reduction in hemoglobin of more than 2 g/dl, and those individuals were considered to be the increased bleeding (IB) group. The concentration of fibrinolytic markers in the anti-Xa group was significantly higher in the IB group than in the non-IB group. There were also no significant differences in the levels of anti-Xa activity, plasminogen activator inhibitor-I, soluble fibrin and antithrombin between the IB and non-IB groups. In conclusion, elevated fibrinolysis induced by increased bleeding may lead to further increases in bleeding in patients receiving thromboprophylaxis with fondaparinux following major orthopedic surgery.

show abstract

Section: Introductionmentioning

confidence: 99%

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Verabreichung nicht 2, sondern 12 h vor dem Eingriff erfolgen sollte. Die Thromboembolieprophylaxe mit Fondaparinux ist der Gabe von NMH (präoperativ) überlegen [16,25,36].…”

Section: Unfallchirurgie Orthopädieunclassified

“…Tag nach Operation) [6,16,25,35,36]. Fondaparinux zeigte eine relative Risikoreduktion von 50% in der Thromboembolieprophylaxe bei vergleichbarer guter Verträglichkeit gegenüber Enoxaparin.…”

Section: Elektiverunclassified

“…Bis zu einer Kreatininclearance von 30-50 ml/h ist durch den Hersteller keine Dosisanpassung empfohlen. Liegt die Kreatininclearance unter 30 ml/h, kommt es zu einer starken Akkumulation, sodass Fondaparinux bei schwerer Niereninsuffizienz kontraindiziert ist.Die Effektivität von Fondaparinux konnte in einer Studie bei Patienten mit Hüftge-lenksersatz nachgewiesen werden[36]. Darüber hinaus konnte in mehreren multizentrischen, doppelblinden, randomisierten Studien mit jeweils mehr als 1.000 Patienten nachgewiesen werden, dass Fondaparinux dem Enoxaparin in der Thromboembolie-Dosierungsbeispiele zur medikamentösen Thromboembolieprophylaxe und therapeutischen Antikoagulation…”

unclassified

See 1 more Smart Citation

Ven�se Thromboembolieprophylaxe

Dohmen

Gogarten²,

Kuhlen

et al. 2004

Anaesthesist

View full text Add to dashboard Cite

Venous thromboembolism is a common and frequent complication of hospitalized patients. Some venous thromboembolisms may be subclinical, while others present as symptomatic deep vein thrombosis and/or pulmonary embolism. Venous thromboembolism and pulmonary embolism contribute significantly to inhospital morbidity and mortality. The risk of venous thromboembolism is aggravated by dispositional and/or expositional risk factors. In patients at intermediate or high risk of venous thromboembolism, additional pharmacological thromboembolism prophylaxis becomes mandatory.

show abstract

“…A recent report of factor Xa antagonists in the prevention of deep vein thrombosis after total hip replacement [50] and ongoing studies with these agents in patients undergoing PCI may provide viable alternative means of anticoagulation for patients with HIT in the future.…”

Section: The Futurementioning

confidence: 99%

Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Mahaffey

2001

Curr Cardiol Rep

View full text Add to dashboard Cite

Heparin-induced thrombocytopenia (HIT) is not uncommon in clinical practice, and may go unrecognized in a substantial number of patients. The pathophysiology of HIT has only recently been better understood. Patients with HIT may require anticoagulation for thrombotic complications that result in severe morbidity and mortality. These patients may also require anticoagulation for acute coronary syndromes (ACS), or during percutaneous coronary interventions (PCIs). The direct thrombin inhibitors are currently the anticoagulant of choice in HIT patients with ACS or those undergoing PCI, based on data from several large clinical trials in ACS and PCI populations, and data from smaller experiences, specifically in patients with HIT.

show abstract

A synthetic pentasaccharide for the prevention of deep-vein thrombosis after total hip replacement

Cited by 51 publications

References 0 publications

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

Increased fibrinolysis increases bleeding in orthopedic patients receiving prophylactic fondaparinux

Ven�se Thromboembolieprophylaxe

Anticoagulation for acute coronary syndromes and percutaneous coronary intervention in patients with heparin-induced thrombocytopenia

Contact Info

Product

Resources

About